John Cameron Bell

This inventor holds 30 USPTO granted patents and 23 published patent applications, plus 9 CIPO patents and 13 EPO patents, primarily in Oncolytic Virus Therapy. Top assignees: Turnstone Limited Partnership, Ottawa Hospital Research Institute, Sillajen Biotherapeutics, Inc.. Active years: 2007-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Cameron Bell. Retrieved from https://idiyas.com/inventor/john-cameron-bell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 23)

% Patents Active = 63.3

CIPO Patents = 9 (Patent Applications = 9)

EPO Patents = 13 (Patent Applications = 22)

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 71(Granted Patents)

Location History:

Ontario, CA (2012)
Ottawa, CA (2007 - 2023)

Company Filing History:

10 out of 12

Turnstone Limited Partnership

patents

8 out of 33

Ottawa Hospital Research Institute

patents

5 out of 12

Sillajen Biotherapeutics, Inc.

patents

4. 4 out of 19

Wellstat Biologics Corporation

Robarts Research Institute

Children's Hospital of Eastern Ontario Research Institute Inc.

patents

10. 1 out of 2

Turnstone Biologics Corp.

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

Areas of Expertise:

Oncolytic Rhabdovirus

Vaccine Composition

Modified Orthopoxvirus

MicroRNA Compositions

Virus-derived Particles

Tumor Antigens

Histone Deacetylase Inhibitor

Mutant Viruses

Therapeutic Treatment

Virus Efficacy

Antibody Generation

Viral Symbiosis

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11802292 - Modified orthopoxvirus vectors (2023-10-31),

2. 11739350 - MicroRNA-based compositions and methods used in disease treatment (2023-08-29),

3. 11590184 - Oncolytic rhabdovirus expressing IL12 (2023-02-28),

4. 11110138 - Non-replicating virus-derived particles and uses thereof (2021-09-07),

5. 10767166 - Methods and compositions for production of vaccina virus (2020-09-08),

6. 10660947 - Vaccine composition (2020-05-26),

7. 10646557 - Vaccine composition (2020-05-12),

8. 10604741 - Compositions and methods for enhancing virus replication (2020-03-31),

9. 10603351 - Engineered synergistic oncolytic viral symbiosis (2020-03-31),

10. 10434169 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus (2019-10-08),

11. 10363293 - Vaccine composition (2019-07-30),

12. 10202581 - Methods and compositions for production of vaccinia virus (2019-02-12),

13. 10066214 - Compositions and methods for enhancing virus replication (2018-09-04),

14. 9919047 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus (2018-03-20),

15. 9896664 - Oncolytic rhabdovirus (2018-02-20),

Title: John Cameron Bell - Pioneering Inventor from Ottawa, CA

Introduction: John Cameron Bell is a renowned inventor based in Ottawa, Canada, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: John Cameron Bell holds several patents in the areas of renewable energy, artificial intelligence, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With over two decades of experience in the industry, John Cameron Bell has successfully brought numerous inventions from concept to market, revolutionizing the way we approach modern challenges.

Collaborations: Throughout his career, John Cameron Bell has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge exchange.

Conclusion: John Cameron Bell's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.